Procainamide

This classification denotes a cation channel blocker and antiarrhythmic agent with the molecular formula C13H21N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) L39WTC366D, chemically known as benzamide, p-amino-n-(2-(diethylamino)ethyl)- but more generally known as procainamide, which bears US NIH Compound Identifier 4913. European Medicines Agency schedules Procainamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10055MIG. The term PROCAINAMIDE is an International Non-Proprietary Name. World Health Organization schedules procainamide in its Anatomical Therapeutic Chemical (ATC) Classification. PROCAINAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule procainamide under HS 29242995 and SITC 51479. As of Q4 2014, PROCAINAMIDE remains US FDA's Preferred Term for this commodity. Procainamide bears US NLM identifiers UMLS ID C0033216 and NCI Concept Code C61905. SMILES: O=C(NCCN(CC)CC)C1CCC(N)CC1.